In a phase 3 trial of 113 adults with moderate-to-severe active thyroid eye disease, veligrotug (5 infusions) vs placebo gave a week-15 proptosis response of 70% vs 5% and overall response of 67% vs 5% (P<0.001); 4% discontinued, with no serious treatment-related events.
RCTn = 113
Yen et al. THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease